Application of gliclazide MR in uncontrolled diabetes type 2 — the treatment phase results of DINAMIC 2 study (V)

Abstract

Tight glycemic control is universally acknowledged as a therapeutic priority in multifactorial management in type 2 diabetes [1, 2]. Achieving control to recommended targets, typically defined as Ł 7% or even Ł 6,5% glycated hemoglobin [1, 2], improves microvascular [3, 4] and possibly macrovascular [4] outcomes, but represents a considerable clinical challenge and carries resource implications. DINAMIC 2 study sampled populations of type 2 diabetic patients attending in primary care settings, in order to generate data about of glycemia [5]. Following this survey phase of the study other data, patients identified as having inadequate control were included into a 6 month trial of the efficacy and acceptability of once-daily sulfonylurea preparation, gliclazide modified release (Diamicron MR), alone or in combination with other oral antidiabetic agents.